| 000 | 01415 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250517173125.0 | ||
| 264 | 0 | _c20180206 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1744-7682 | ||
| 024 | 7 |
_a10.1080/14712598.2017.1377178 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSaid, Rabih | |
| 245 | 0 | 0 |
_aObinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. _h[electronic resource] |
| 260 |
_bExpert opinion on biological therapy _c11 2017 |
||
| 300 |
_a1463-1470 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntigens, CD20 _ximmunology |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, B-Cell _xdrug therapy |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy |
| 650 | 0 | 4 |
_aNeutropenia _xetiology |
| 700 | 1 | _aTsimberidou, Apostolia M | |
| 773 | 0 |
_tExpert opinion on biological therapy _gvol. 17 _gno. 11 _gp. 1463-1470 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/14712598.2017.1377178 _zAvailable from publisher's website |
| 999 |
_c27548170 _d27548170 |
||